new glp 1 drug retatrutide GLP-1 obesity drug, retatrutide, shows added benefits Trial of next-gen weight-loss drug
Description
Absorption and disposition of ampicillin in the elderly

[5] Understanding the context is essential for both patients and healthcare professionals
Lixisenatide in patients with type 2 diabetes and Acute Coronary Syndrome

Liraglutide inhibited AGEs induced coronary smooth muscle cell phenotypic transition through inhibiting the NF-B signal pathway
1.5% vs 0.9%point), dulaglutide (semaglutide 0.5 mg vs dulaglutide 0.75 mg, 1.5% vs 1.1%point

Additional clinical studies involving liraglutide and dulaglutide are ongoing